Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03555487
Other study ID # 201411046MINB
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date May 5, 2015
Est. completion date October 1, 2018

Study information

Verified date June 2019
Source National Taiwan University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective study aims to

1. compare the detection rates among sonography, MIBI scan and 18F-FCH PET for localization of the parathyroid lesions including adenoma, hyperplasia or carcinoma; evaluate the usefulness of 18F-FCH PET as a second-line tracer in MIBI scan negative patients.


Description:

Hyperparathyroidism is a common endocrine disorder. Primary hyperparathyroidism is due to over-secretion of parathyroid hormone and subsequently hypercalcemia, phyophosphatemia and osteoporosis, while secondary hyperparathyroidism is due to physiological secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia. Surgical approach is the major treatment modality for majority of these patients with hyperparathyroidism. Pre-operative localization of hyperfunctioning glands may lead to minimally invasive surgery. The most commonly used imaging modality for this purpose is 99mTc-sestaMIBI, and supplemented by ultrasonography of the neck. However, the sensitivity and specificity is significantly lower in patients with multiple parathyroid lesions.

Recently, some investigators reported cases of parathyroid adenoma discovered incidentally on choline PET images performed for prostate cancer. 11C or 18F choline is a PET probe used in imaging prostate cancer and hepatocellular carcinoma. As a phospholipid analog, choline is integrated into newly synthesized membranes of proliferating cells by up-regulation of choline kinase. In addition, a previous study showed that the activity of phospholipid/Ca2+-dependent protein kinase was also higher in hyper-functioning parathyroid tissue than in atrophic parathyroid gland. Both mechanisms may be responsible for the uptake of choline tracers in hyperfunctioning parathyroid tissue. Up to now, there are only 3 original reports with limited patients using choline PET in the evaluation of hyperparathyroidism.

This prospective study aims to

1. compare the detection rates among sonography, MIBI scan and 18F-FCH PET for localization of the parathyroid lesions including adenoma, hyperplasia or carcinoma;

2. evaluate the usefulness of 18F-FCH PET as a second-line tracer in MIBI scan negative patients.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date October 1, 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Parahyperthyroidism (serum iPTH 65 pg / mL; normal range : 12-65), merged with normal or high serum calcium concentration (serum calcium 2.35 mmol / L; normal range: 2.15-2.58) and normal or low serum phosphate concentration (serum phosphorus 3.75 mg / dL; normal range : 2.5-5.0).

- High serum calcium concentration (serum calcium 2.58 mmol/L), but the blood parathyroid hormone concentration in normal range (serum iPTH 12-65pg / mL), hyperthyroidism is suspected.

- MIBI scan has been performed or arranged.

- Age:above 20 years old.

Exclusion Criteria:

- Patient with Familial hypocalciuric hypercalcemia:daily calcium excretion < 100 mg/24h and fractional excretion of calcium < 1%.

- taking or was taking lithium.

- vitamin D deficiency (25-OH vitamin D < 10 ng/mL).

- Patients with pregnancy or recently having a plan for pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
18F-choline PET
5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.

Locations

Country Name City State
Taiwan National Taiwan Univeristy Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary PET imaging By visual interpretation if there are focal areas of abnormal 18F-FCH accumulation. The presence, number, size, character, and location of suspected lesions will be filed for each patient in this study. in 3 days
See also
  Status Clinical Trial Phase
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Completed NCT00569920 - Nausea and Pain Prophylaxis During Thyroid Surgery N/A
Terminated NCT00639405 - Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas N/A
Completed NCT04704349 - Latest Imaging SPECT System Evaluation Phase 1 N/A
Completed NCT03747029 - Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Completed NCT03640247 - Pain Medications Following Thyroidectomy and Parathyroidectomy Phase 1
Completed NCT04344886 - Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery N/A
Completed NCT03469310 - Minimizing Narcotic Analgesics After Endocrine Surgery Phase 4
Not yet recruiting NCT05243979 - The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut
Active, not recruiting NCT05778071 - Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism Phase 3
Completed NCT02901873 - EIS in Thyroid and Parathyroid Surgery N/A
Recruiting NCT04569513 - The Analysis of Thyroidectomy and Parathyroidectomy
Recruiting NCT05387070 - PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism Phase 3
Not yet recruiting NCT05432050 - Bispectral Index and Patient State Index During General Anesthesia With Remimazolam
Recruiting NCT06274970 - PaThERAS: ERAS Protocols in Thyroid & Parathyroid Surgery N/A
Enrolling by invitation NCT05294393 - Ropivacaine Plus Magnesium Sulphate Infiltration Phase 4
Terminated NCT04745793 - Precise Recognition With Enhanced Vision of Endocrine Neck Targets
Recruiting NCT05152927 - Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Active, not recruiting NCT04701203 - A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism Phase 3
Recruiting NCT05022667 - Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy N/A